China has granted its first COVID-19 vaccine patent to the adenovirus vector vaccine developed by CanSino Biologics, reported China Daily.
According to China's National Intellectual Property Administration, the patent was submitted for application on March 18, and was approved on August 11.
The vaccine, dubbed Ad5-nCoV, uses a weakened common cold virus to introduce genetic material from SARS-CoV-2 into the human body.
The Phase II trial of the vaccine has found it is safe and can induce an immune response, according to research published in The Lancet last month.
However, compared with younger people, older participants generally had significantly lower immune responses, the study found. As a result, elderly people might require an additional dose to induce a stronger immune response.
Meanwhile, a late-stage clinical trial, which will include more participants and be conducted overseas, is currently in the pipeline.
To read more NewsPoints articles, click here.